Roger Li, MD, on Combining Adenovirus CG007 With Pembrolizumab in Bladder Cancer

Posted: Friday, December 2, 2022

Roger Li, MD, of the H. Lee Moffitt Cancer Center, discusses the practical considerations of his findings on combining the adenovirus CG0070 with pembrolizumab in patients with non–muscle-invasive bladder cancer: the current standard of care, the underlying mechanism of the virus, adverse events, and next steps in the evolution of treatment.